文献速递胸部肿瘤

电子鼻分析呼气预测非小细胞肺癌抗PD-1治疗反应

Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath.
PubMed 文献 · Ann Oncol · 2019-01-01

这项前瞻性观察研究纳入143例接受纳武利尤单抗或帕博利珠单抗治疗的NSCLC患者,基线呼气谱用金属氧化物半导体电子鼻采集。训练集92例、验证集51例。提示呼气分析可无创预测抗PD-1治疗反应。

要点

  • 基线呼气电子鼻分析可预测NSCLC患者3个月抗PD-1治疗反应。
  • 该无创方法有望避免对可能无反应者使用无效免疫治疗。

核心结论

  • 电子鼻评估可有效无创预测NSCLC患者对免疫治疗的个体反应,并在独立验证集中重复了区分免疫治疗反应类型的预测准确性和效能。

研究设计与样本

  • 前瞻性观察研究,纳入接受检查点抑制剂治疗的NSCLC患者,分为训练集92例和验证集51例,共143例。
  • 基线用金属氧化物半导体电子鼻在 pneumotachograph 后端重复采集呼气谱,患者接受纳武利尤单抗或帕博利珠单抗,3个月随访时按RECIST 1.1评估疗效。

主要发现

  • 143例NSCLC患者基线呼气数据可用(训练92例,验证51例)。
  • 基线电子鼻传感器在区分抗PD-1治疗3个月时不同反应患者中贡献显著(P < 0.05)。

临床怎么用

  • 基线呼气电子鼻分析可用于无创预测NSCLC患者抗PD-1治疗反应,帮助识别可能无反应者以避免无效治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors have improved survival outcome of advanced non-small-cell lung cancer (NSCLC). However, most patients do not benefit. Therefore, biomarkers are needed that accurately predict response. We hypothesized that molecular profiling of exhaled air may capture the inflammatory milieu related to the individual responsiveness to anti-programmed death ligand 1 (PD-1) therapy. This study aimed to determine the accuracy of exhaled breath analysis at baseline for assessing nonresponders versus responders to anti-PD-1 therapy in NSCLC patients. METHODS: This was a prospective observational study in patients receiving checkpoint inhibitor therapy using both a training and validation set of NSCLC patients. At baseline, breath profiles were collected in duplicate by a metal oxide semiconductor electronic nose (eNose) positioned at the rear end of a pneumotachograph. Patients received nivolumab or pembrolizumab of which the efficacy was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 at 3-month follow-up. Data analysis involved advanced signal-processing and statistics based on independent t-tests followed by linear discriminant and receiver operating characteristic (ROC) analysis. RESULTS: Exhaled breath data of 143 NSCLC patients (training: 92, validation: 51) were available at baseline. ENose sensors contributed significantly (P < 0.05) at baseline in differentiating between patients with different responses at 3 months of anti-PD-1 treatment. The eNose sensors were combined into a single biomarker with an ROC-area under the curve (AUC) of 0.89 [confidence interval (CI) 0.82-0.96]. This AUC was confirmed in the validation set: 0.85 (CI 0.75-0.96). CONCLUSION: ENose assessment was effective in the noninvasive prediction of individual patient responses to immunotherapy. The predictive accuracy and efficacy of the eNose for discrimination of immunotherapy responder types were replicated in an independent validation set op patients. This finding can potentially avoid application of ineffective treatment in identified probable nonresponders.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. de Vries R, Muller M, van der Noort V, et al. Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath. Ann Oncol. 2019. PMID: 31529107. doi:10.1093/annonc/mdz279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。